ALB and Parkinson disease: Our neurobehavioral results showed that dopamine encapsulated in albumin/PLGA nanosystems at the highest dose used displayed significant symptomatic improvements when compared to untreated animals with Parkinson’s disease-like symptoms and to group treated with bulk L-DOPA, currently used in patients as frontline treatment against PD.